Pediatric psoriasis patients may experience comorbidities, including psychiatric comorbidities, at a greater rate than children without the disease, according to a study published in May 2019 in Pediatric Dermatology.1 But the incidence of comorbidities doesn’t seem to be impacted by disease severity, says study authors.
Psoriasis impacts the lives of approximately 0.1% of children in the United States,2 and, according to recent studies, the incidence of psoriasis rises linearly with age reaching 1.3% after puberty.2-4 It is well known that psoriasis carries with it the risk of developing other serious health conditions, but little is known about the prevalence of comorbidities in pediatric psoriasis patients.
Investigators at the Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Ill., looked to fill this gap by completing a retrospective cohort study to evaluate the incidence of comorbidities in pediatric patients with psoriasis.
Researchers gathered retrospective data from the MarketScan Commercial Claims and Encounters Database between January 1, 2009, and June 30, 2015. The database includes inpatient, outpatient and outpatient prescription drug information from 190,000,000 unique patients between 1996 and 2017. The information includes detailed cost, use and outcomes data for healthcare services performed in both inpatient and outpatient settings.
Investigators used this database to classify patients aged 4 to 17 years into a psoriasis cohort and a non-psoriasis cohort using administrative claims to confirm diagnosis of psoriasis. Of the 38,430 patients that were included in the study, 7,686 had psoriasis and 30,744 did not. For the comparison, study authors paired three relatively healthy patients without psoriasis with every psoriasis patient. They found that, in the psoriasis cohort, the prevalence per 1000 patients of any comorbidity was 49.05; while the prevalence per 1000 patients of any comorbidity in the non-psoriasis cohort was 11.94.
1. Paller AS, Schenfeld J, Accortt NA, Kricorian G. A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis population. Pediatr Dermatol. 2019;36(3):290–297.
2. Burden-teh E, Thomas KS, Ratib S, Grindlay D, Adaji E, Murphy R. The epidemiology of childhood psoriasis: a scoping review. Br J Dermatol. 2016;174(6):1242-57.
3. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141(12):1537-41.
4. Olsen AO, Grjibovski A, Magnus P, Tambs K, Harris JR. Psoriasis in Norway as observed in a population-based Norwegian twin panel. Br J Dermatol. 2005;153(2):346-51.